Adding bevacizumab to standard chemotherapy improves overall survival for women with ovarian cancer
the ONA take:
Preliminary findings from the Gynecologic Oncology Group’s (GOG) GOG 213 study show an improvement in overall survival for women with ovarian cancer when bevacizumab is added to standard chemotherapy. The researchers report overall survival was a median 5 months longer for women who received chemotherapy plus bevacizumab than for women who received chemotherapy alone. These findings were presented at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer.
Median overall survival for women in the chemotherapy plus bevacizumab group was 42.2 months, compared with 37.3 months in the group who received chemotherapy alone. The additional drug improved progression-free survival by nearly 3.5 months (13.8 months for chemotherapy plus bevacizumab vs 10.4 months for chemotherapy alone). The ongoing study will assess quality of life in the women who also received bevacizumab and the role of secondary surgery before chemotherapy.
Preliminary findings from the Gynecologic Oncology Group’s (GOG) GOG 213 study show an improvement in overall survival for women with ovarian cancer when bevacizumab is added to standard chemotherapy.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|